v3.24.0.1
Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 12 Months Ended
Feb. 12, 2024
Jan. 01, 2024
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Feb. 28, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Other acquisitions and investments             $ (1,223) $ (539) $ (1,377)  
Acquired IPR&D and milestones             778 697 1,124  
Gain (Loss) on Disposition of Other Assets             0 172 68  
Other operating expense (income), net             (179) 56 432  
Cerevel Therapeutics | Subsequent event                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Cash per share received by shareholders (in dollars per share)   $ 45.00                
ImmunoGen | Subsequent event                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Cash per share received by shareholders (in dollars per share) $ 31.26                  
Forecast | Cerevel Therapeutics | Subsequent event                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Total consideration   $ 8,700                
Forecast | ImmunoGen | Subsequent event                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Total consideration $ 10,100                  
Collaborative arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Research and Development Milestone Expenses             196 252 162  
Syndesi Therapeutics SA                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Acquired IPR&D and milestones       $ 130            
Syndesi Therapeutics SA | Collaborative arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Potential additional milestone payments                   $ 870
Juvise Pharmaceuticals                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Proceeds from Sale of Other Assets     $ 215              
TeneoOne | Collaborative arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Acquired IPR&D and milestones           $ 400        
TeneoOne | Maximum | Collaborative arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Potential additional milestone payments           250        
REGENXBIO Inc. | Collaborative arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Acquired IPR&D and milestones         $ 370          
REGENXBIO Inc. | Maximum | Collaborative arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Potential additional milestone payments           1,400        
Other individually insignificant arrangements | Collaborative arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Acquired IPR&D and milestones             582 $ 315 $ 192  
Other individually insignificant arrangements | Maximum | Collaborative arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Potential additional milestone payments             $ 10,900      
Calico Life Sciences LLC | Collaborative arrangement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Additional contribution to collaboration           500        
Additional contribution to collaboration by partner           500        
Other operating expense (income), net           $ (500)        
Other operating income | Juvise Pharmaceuticals                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions                    
Gain (Loss) on Disposition of Other Assets     $ 172